Idacio

Adalimumab, the active ingredient in Idacio, is a TNF-alpha inhibitor presented as a 40 mg prefilled syringe for subcutaneous use. It treats autoimmune inflammatory conditions such as rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, plaque psoriasis, Crohn’s disease, ulcerative colitis and hidradenitis suppurativa in adult patients.

GNH USA supplies Idacio as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, ensuring quality and regulatory compliance.

Idacio (adalimumab) is a TNF-alpha inhibitor used to manage several chronic inflammatory and autoimmune diseases. - Rheumatoid arthritis: reduces joint inflammation and slows structural damage. - Psoriatic arthritis: alleviates joint pain and skin lesions. - Ankylosing spondylitis: improves spinal mobility and reduces pain. - Plaque psoriasis: clears skin plaques and decreases scaling. - Crohn's disease: induces and maintains remission of intestinal inflammation. - Ulcerative colitis: helps achieve clinical remission and mucosal healing. - Hidradenitis suppurativa: decreases lesion count and severity.

Common Side Effects: - Injection site reactions (pain, redness, swelling) - Upper respiratory tract infections - Headache - Nausea

Serious or Rare Side Effects: - Serious infections such as tuberculosis or sepsis - Malignancies including lymphoma and skin cancer - Hepatic injury or elevated liver enzymes

Before starting Idacio, consider the following precautions: - Screen for latent TB before initiating therapy: perform tuberculin skin test or interferon‑γ release assay. - Monitor for signs of infection during treatment: report fever, cough, or unusual symptoms promptly. - Assess liver function periodically: check ALT/AST levels. - Avoid live vaccines while receiving adalimumab: use inactivated vaccines only. - Pregnancy and breastfeeding: discuss risks with healthcare provider; safety data are limited. - Store at 2-8 °C: keep refrigerated, protect from light, do not freeze or shake.

Adalimumab may interact with the following agents: Major Interactions (Avoid): - Live vaccines: may cause severe infection; avoid concurrent use. - Concomitant use with other biologic immunosuppressants: increased risk of infection. Moderate Interactions (Monitor Closely): - Methotrexate or azathioprine: may increase immunosuppression, monitor labs. - Cyclosporine: may increase risk of infection. - Inactivated vaccines: may have reduced efficacy, monitor response.